Cleared Traditional

K860371 - ASSERACHROM VWF KIT

K860371 is the FDA 510(k) clearance for ASSERACHROM VWF KIT by American Bioproducts Co.. It is a Class 2 Hematology device (product code GGP) cleared through the Traditional 510(k) pathway after a 60-day FDA review.

K860371 · American Bioproducts Co. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1986
Decision
60d
Days
Class 2
Risk

K860371 is an FDA 510(k) clearance for the ASSERACHROM VWF KIT. Classified as Test, Qualitative And Quantitative Factor Deficiency (product code GGP), Class II - Special Controls.

Submitted by American Bioproducts Co. (Parsippany, US). The FDA issued a Cleared decision on April 4, 1986 after a review of 60 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7290 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all American Bioproducts Co. devices

Submission Details

510(k) Number K860371 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 03, 1986
Decision Date April 04, 1986
Days to Decision 60 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
53d faster than avg
Panel avg: 113d · This submission: 60d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GGP Test, Qualitative And Quantitative Factor Deficiency
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7290
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GGP Test, Qualitative And Quantitative Factor Deficiency

All 126
Devices cleared under the same product code (GGP) and FDA review panel - the closest regulatory comparables to K860371.
HIGH MOLECULAR WEIGHT KININOGEN(HMWK) DEF PLASMA
K861049 · Sigma Chemical Co. · May 1986
VWF-IX:AG CONTROL PLASMA
K861217 · American Bioproducts Co. · May 1986
PROTEIN C CONTROL PLASMA
K861216 · American Bioproducts Co. · May 1986
ASSERACHROM IX:AG
K854312 · American Bioproducts Co. · Feb 1986
ASSERA PLATE IX:AG KIT
K854014 · American Bioproducts Co. · Jan 1986
COAGULATION FACTOR IX DEFICIENT SUBSTRATE PLASMA
K853461 · American Dade · Aug 1985